Adaptimmune Therapeutics PLC expected to post a loss of 24 cents a share - Earnings Preview

Adaptimmune Therapeutics

07/08/2021 01:54

* Adaptimmune Therapeutics PLC  ADAP.OQ   ADAP.O  is expected
to show a rise in quarterly revenue when it reports results on
August 9. 
* The Abingdon, Oxfordshire-based company is expected to report 
 a 170.3% increase in revenue to $1.357 million from $502
thousand a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Adaptimmune
Therapeutics PLC is for a loss of 24 cents per share. For the
same quarter last year, the company reported a loss of 24 cents
per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $9​, about 61.2% above​ its last closing
price of $3.49. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.25       -0.25      -0.24     Beat    4
 Dec. 31 2020  -0.23       -0.23      -0.24     Missed  -3.3
 Sep. 30 2020  -0.25       -0.25      -0.24     Beat    5.5​
 Jun. 30 2020  -0.24       -0.24      -0.24     Met     -2
 Mar.          -0.26​      -0.25      -0.24     Beat    5.3​
 31​ 2020​                                              
 Dec. 31 2019  -0.33       -0.34      -0.30     Beat    11.9​
 Sep. 30 2019  -0.31       -0.31      -0.36     Missed  -17.8
 Jun. 30 2019  -0.35       -0.35      -0.39     Missed  -10.8
 This summary was machine generated August 7 at 00:54 GMT.  All
figures in US dollars unless otherwise stated